Unoprostone (INN) is a prostaglandin analogue.

Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.

[1][2] It was approved by the Food and Drug Administration in 2000.

[3] In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.

[4] In 2015, the drug was discontinued in the U.S.[citation needed] This pharmacology-related article is a stub.